2:11 PM
 | 
Dec 07, 2017
 |  BC Extra  |  Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower150 trial of Tecentriq atezolizumab as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer, including results from a subgroup of patients with a T effector (Teff) gene signature expression biomarker. Teff measures mRNA expression of PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG) and interferon (IFN) gamma.

Tecentriq is already approved in the U.S. to treat metastatic NSCLC in patients who have progressed during or following platinum-containing chemotherapy. Genentech said it plans to submit...

Read the full 437 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >